CA2774021A1 - Use of opioid receptor antagonist for gastrointestinal tract disorders - Google Patents

Use of opioid receptor antagonist for gastrointestinal tract disorders Download PDF

Info

Publication number
CA2774021A1
CA2774021A1 CA2774021A CA2774021A CA2774021A1 CA 2774021 A1 CA2774021 A1 CA 2774021A1 CA 2774021 A CA2774021 A CA 2774021A CA 2774021 A CA2774021 A CA 2774021A CA 2774021 A1 CA2774021 A1 CA 2774021A1
Authority
CA
Canada
Prior art keywords
compound
opioid
effective amount
therapeutically effective
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2774021A
Other languages
English (en)
French (fr)
Inventor
Richard M. Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adolor Corp
Original Assignee
Adolor Corp
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2774021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adolor Corp, Merck Sharp and Dohme LLC filed Critical Adolor Corp
Publication of CA2774021A1 publication Critical patent/CA2774021A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2774021A 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders Abandoned CA2774021A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24361609P 2009-09-18 2009-09-18
US61/243,616 2009-09-18
PCT/US2010/049311 WO2011035142A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Publications (1)

Publication Number Publication Date
CA2774021A1 true CA2774021A1 (en) 2011-03-24

Family

ID=43216894

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774021A Abandoned CA2774021A1 (en) 2009-09-18 2010-09-17 Use of opioid receptor antagonist for gastrointestinal tract disorders

Country Status (19)

Country Link
US (1) US20110071163A1 (https=)
EP (1) EP2477627B1 (https=)
JP (1) JP5797655B2 (https=)
KR (1) KR20120092592A (https=)
CN (2) CN104958298A (https=)
AU (1) AU2010295464B2 (https=)
BR (1) BR112012006069A8 (https=)
CA (1) CA2774021A1 (https=)
CL (1) CL2012000676A1 (https=)
CO (1) CO6531453A2 (https=)
HK (1) HK1210959A1 (https=)
IL (1) IL218679A0 (https=)
MX (1) MX342548B (https=)
NZ (1) NZ598783A (https=)
PE (1) PE20120991A1 (https=)
RU (1) RU2561873C2 (https=)
TW (1) TW201118084A (https=)
WO (1) WO2011035142A1 (https=)
ZA (1) ZA201201954B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014102571A1 (en) * 2012-12-28 2014-07-03 Instytut Medycyny Doswiadczalnej I Klinicznej Im. Miroslawa Mossakowskiego Polskiej Akademii Nauk Peptidomimetics and their application
TN2018000355A1 (en) 2016-05-20 2020-06-15 Esteve Pharmaceuticals Sa Tetrahydropyran and thiopyran derivatives having multimodal activity against pain.
CN106117190B (zh) * 2016-06-21 2019-03-29 山东川成医药股份有限公司 一种倍福普兰的合成方法
CN113573711A (zh) 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191771A (en) * 1974-09-06 1980-03-04 Eli Lilly And Company Analgesic method using 1,3,4-trisubstituted-4-arylpiperidines
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5319087A (en) * 1987-04-16 1994-06-07 Eli Lilly And Company Piperidine opioid antagonists
US5064834A (en) * 1987-04-16 1991-11-12 Eli Lilly And Company Piperidine opioid antagonists
US4992450A (en) * 1987-04-16 1991-02-12 Eli Lilly And Company Piperidine opioid antagonists
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0759303B1 (en) 1994-04-22 2002-10-16 Yamanouchi Pharmaceutical Co. Ltd. Colon-specific drug release system
US5378448A (en) * 1994-06-07 1995-01-03 Lin; Hsing K. Process for removing selenium from sulfur
TW490465B (en) * 1994-11-24 2002-06-11 Janssen Pharmaceutica Nv Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
BRPI0014869B8 (pt) * 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
CA2549009A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) * 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
ATE399164T1 (de) * 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005022572D1 (de) * 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
RU2482107C2 (ru) * 2007-12-11 2013-05-20 Тереванс, Инк. Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора
JP5650657B2 (ja) * 2008-12-10 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−カルボキシプロピル−アミノテトラリン化合物の結晶形態
TR201908514T4 (tr) * 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇

Also Published As

Publication number Publication date
ZA201201954B (en) 2012-11-28
JP2013505260A (ja) 2013-02-14
NZ598783A (en) 2013-07-26
MX342548B (es) 2016-10-04
EP2477627B1 (en) 2018-08-15
EP2477627A1 (en) 2012-07-25
AU2010295464A1 (en) 2012-04-12
PE20120991A1 (es) 2012-08-01
BR112012006069A8 (pt) 2017-10-10
IL218679A0 (en) 2012-05-31
WO2011035142A1 (en) 2011-03-24
MX2012003310A (es) 2012-07-17
JP5797655B2 (ja) 2015-10-21
CO6531453A2 (es) 2012-09-28
AU2010295464B2 (en) 2015-11-26
CN102695508A (zh) 2012-09-26
TW201118084A (en) 2011-06-01
HK1210959A1 (en) 2016-05-13
CN104958298A (zh) 2015-10-07
RU2012115450A (ru) 2013-10-27
CL2012000676A1 (es) 2012-10-19
KR20120092592A (ko) 2012-08-21
RU2561873C2 (ru) 2015-09-10
BR112012006069A2 (pt) 2016-03-29
US20110071163A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
Reimer et al. Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach
Burness et al. Oxycodone/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation
WO2007005716A2 (en) Methods of treatment and compositions for use thereof
US20200163958A1 (en) Use of methylnaltrexone to attenuate tumor progression
KR101630467B1 (ko) 진통 내성 억제제
AU2010295464B2 (en) Use of opioid receptor antagonist for gastrointestinal tract disorders
AU2019203694A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
Neary et al. Alvimopan
JP2014515405A (ja) オピオイド受容体アゴニストの逐次投与のための組成物
JP2006131545A (ja) 神経因性疼痛治療剤
US11642341B2 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
Holzer Methylnaltrexone for the management of unwanted peripheral opioid effects
Kareem et al. Mu-opioid receptor antagonists and their role in treatment of chronic constipation
WO2015191686A1 (en) Methods of administering methylnaltrexone
US20080287480A1 (en) Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
Hipkin et al. Opioid receptor antagonists for gastrointestinal dysfunction
US20060025434A1 (en) Therapeutic agents for drug/substance dependence
HK1245013A1 (en) Use of methylnaltrexone to attenuate tumor progression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150909

FZDE Discontinued

Effective date: 20191219